Biocytogen Pharmaceuticals (Beijing) Valuation
Is 2315 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2315 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2315's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2315's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2315?
Key metric: As 2315 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 2315's PS Ratio? | |
|---|---|
| PS Ratio | 2.6x |
| Sales | CN¥800.58m |
| Market Cap | CN¥2.11b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.8x |
| Enterprise Value/EBITDA | 167x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2315's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.3x | ||
2616 CStone Pharmaceuticals | 5.1x | 34.3% | HK$2.5b |
2509 Qyuns Therapeutics | 31.5x | n/a | HK$2.0b |
2487 Cutia Therapeutics | 11.9x | 41.4% | HK$2.6b |
2256 Abbisko Cayman | 4.9x | 8.8% | HK$2.6b |
2315 Biocytogen Pharmaceuticals (Beijing) | 2.6x | 22.4% | HK$2.3b |
Price-To-Sales vs Peers: 2315 is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (13.3x).
Price to Sales Ratio vs Industry
How does 2315's PS Ratio compare vs other companies in the HK Biotechs Industry?
| 14 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 11.2x | 29.3% | |
2315 Biocytogen Pharmaceuticals (Beijing) | 2.6x | 22.4% | US$290.92m |
6826 Shanghai Haohai Biological Technology | 2.1x | 11.8% | US$1.79b |
1530 3SBio | 1.4x | 9.3% | US$1.67b |
| 14 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 11.2x | 42.6% | |
2315 Biocytogen Pharmaceuticals (Beijing) | 2.6x | n/a | US$290.92m |
Price-To-Sales vs Industry: 2315 is good value based on its Price-To-Sales Ratio (2.6x) compared to the Hong Kong Biotechs industry average (11.2x).
Price to Sales Ratio vs Fair Ratio
What is 2315's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.6x |
| Fair PS Ratio | 3.4x |
Price-To-Sales vs Fair Ratio: 2315 is good value based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (3.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
3SBio
HK$13.0b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.52
7D
-4.3%
1Y
-26.2%
China Shineway Pharmaceutical Group
HK$6.1b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.13
7D
-3.3%
1Y
n/a
China Shineway Pharmaceutical Group
HK$6.1b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.13
7D
-3.3%
1Y
n/a